HomeAI · summaries
Storia in 6 fonti
Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue
Lilly posts $23B in Q2 revenue, beating estimates by $3B as tirzepatide hits 64% of revenue; raises full year guidance to $85B–$87B.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth
In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more
- ·
cnbc.com
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
